Evaluation of IgM and IgG in COVID-۱۹ Recovered Patients in Iraq

Publish Year: 1401
نوع سند: مقاله ژورنالی
زبان: English
View: 293

This Paper With 7 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_ARCHRAZI-77-3_032

تاریخ نمایه سازی: 6 دی 1402

Abstract:

Severe acute respiratory syndrome coronavirus-۲ is a major threat to health care worldwide with high morbidity and mortality. Therefore, understanding the role of immune mechanisms and humoral response is vital in this disease. The present study aimed to investigate the relationship between Immunoglobulins (IgM, IgG) in COVID-۱۹ recovered patients with age, gender, and severity of the disease. The duration of effect of antibody levels and protection against re-infection has also been evaluated in the patients. Three groups participated in this study; group ۱:  ۰-۱۴ days after recovery, group ۲: ۲ months after recovery, group ۳: ۳ months after recovery, group ۴: ۴-۶ months after recovery, group ۵: more than ۶ months. The nasopharyngeal swab was used to confirm recovery by Real-Time Polymerase Chain Reaction (RT-PCR) technique. IgM and IgG antibody levels were evaluated using Enzyme-Linked Immuno Fluorescent Assay (ELIFA) technique. The results indicated that the IgM levels increased for one month during the seven days after infection and then decreased in most patients (P≤۰.۰۵). The mean of IgG in group ۱ increased compared to those of other studied groups. A significant decrease was observed in group ۲ compared to group ۱, as well as in group ۳ compared to groups ۱, and ۲. Also, a significant difference existed between group ۴ compared to groups ۱, ۲, and ۳. Finally, significant differences were noticed between group ۵ compared to groups ۱, ۲, ۳, and ۴ (P≤۰.۰۵). No significant differences were observed in antibodies level between male, and female COVID-۱۹ recovered patients in groups ۱, ۲, ۳, ۴, and ۵ (P≤۰.۰۵).  Finally, highly significant differences in IgG levels between mild, moderate, and severe subgroups in groups ۱ and ۲. The present study demonstrated that IgM and IgG against SARS-CoV-۲ appeared in the early stages of the disease and decreased after ۱ month and failed to maintain high levels during the ۶-month observation.

Authors

S Muslim Dawood

Educational Laboratories, Unit of Clinical Immunology, Baghdad Medical City, Baghdad, Iraq

I Khudhur Al Joofy

Department of Biology, College of Science, Mustansiriyah University, Baghdad, Iraq

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • Astuti I, Ysrafil. Severe Acute Respiratory Syndrome Coronavirus ۲ (SARS-CoV-۲): ...
  • Naqvi AAT, Fatima K, Mohammad T, Fatima U, Singh IK, ...
  • Wang D, Hu B, Hu C, Zhu F, Liu X, ...
  • Chan KW, Wong VT, Tang SCW. COVID-۱۹: An Update on ...
  • Kong WH, Li Y, Peng MW, Kong DG, Yang XB, ...
  • Alifano M, Alifano P, Forgez P, Iannelli A. Renin-angiotensin system ...
  • Calcagnile M, Forgez P, Iannelli A, Bucci C, Alifano M, ...
  • Debnath M, Banerjee M, Berk M. Genetic gateways to COVID-۱۹ ...
  • Devaux CA, Rolain JM, Raoult D. ACE۲ receptor polymorphism: Susceptibility ...
  • Godri Pollitt KJ, Peccia J, Ko AI, Kaminski N, Dela ...
  • Zhu N, Zhang D, Wang W, Li X, Yang B, ...
  • Commission NH. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia ...
  • VirgilioParadiso A, De Summa S, Loconsole D, Procacci V, Sallustio ...
  • Wolfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, ...
  • Edridge AWD, Kaczorowska J, Hoste ACR, Bakker M, Klein M, ...
  • Carvalho-Schneider C, Laurent E, Lemaignen A, Beaufils E, Bourbao-Tournois C, ...
  • De Donno A, Lobreglio G, Panico A, Grassi T, Bagordo ...
  • Mukherjee S, Pahan K. Is COVID-۱۹ Gender-sensitive? J Neuroimmune Pharmacol. ...
  • Guo L, Ren L, Yang S, Xiao M, Chang, Yang ...
  • Liu X, Wang J, Xu X, Liao G, Chen Y, ...
  • Huang AT, Garcia-Carreras B, Hitchings MDT, Yang B, Katzelnick LC, ...
  • Liu W, Fontanet A, Zhang PH, Zhan L, Xin ZT, ...
  • Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, ...
  • Mo H, Zeng G, Ren X, Li H, Ke C, ...
  • Seow J, Graham C, Merrick B, Acors S, Pickering S, ...
  • Wang X, Guo X, Xin Q, Pan Y, Hu Y, ...
  • Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, ...
  • Zhao J, Yuan Q, Wang H, Liu W, Liao X, ...
  • Fajnzylber J, Regan J, Coxen K, Corry H, Wong C, ...
  • Hu B, Huang S, Yin L. The cytokine storm and ...
  • Ye Q, Wang B, Mao J. The pathogenesis and treatment ...
  • نمایش کامل مراجع